累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
蓝印在2024年JMP会议上宣布停止对blu-945早期临床药物的进一步投资了,不知道接下来会不会停止内部开发,唉,这个药感觉希望不大。 Discontinue further investment in the early clinical-stage therapies BLU-945 and BLU-451 for EGFR-mutant NSCLC and explore strategic options, including potential out-licensing, based on the evolving external landscape and emerging clinical data.—— Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference |
|
|
|